September 2017CROss Alliance® is glad to communicate the official agreement signature with Redwood Pharma AB for the set-up, coordination and management of a phase II clinical study with RP101: Redwood Pharma’s leading drug candidate for the treatment of dry eye disease in post-menopausal females.

This new clinical study, to be performed with a scientifically innovative drug product (RP101), confirms once more the capabilities of CROss Alliance® group to support with professionalism and adequate flexibility large phase II PoC studies.

All details available at: